With Child Deaths Projected to Rise for the First Time This Century, Gates Foundation Urges Global Leaders to Target Scarce Resources Where They Save the Most Lives
New Goalkeepers Report models impact of global health funding cuts, offers roadmap of best buys and most effective investments to slow this reversal SEATTLE, Dec. 4, 2025 /PRNewswire/ -- The number of children dying before their 5th birthday is projected to rise for the first time this century, reversing decades of global progress, according to new data published today...
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr. Hongjiang Miao as Chief AI Officer. Dr. Miao will be based in Shanghai...
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annual Asia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for its 2026 Breakthrough meeting, offering researchers globally the opportunity to present and discuss findings...
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") of the PRC, with the proposed indication for the treatment of adults with...
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025)...
POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2024 June 30, 2025 June 30, 2025 RMB RMB US$ Assets ...
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO, Calif., Dec. 4, 2025 /PRNewswire/ -- ImpriMed, a precision oncology CRO specializing in ex vivo drug sensitivity testing for hematologic malignancies, announced today that it has been selected to present two significant research studies at the 67th American Society of Hematology...
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug development and operational excellence to propel Emerald's continued growth. SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization (CRO), today announced the appointment of Luke Gill, MSc, MBA, as Vice President, Global Head of Oncology,...
Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results, Net profit rises 60.1% year-on-year
BEIJING, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the three months ended September 30,2025. During the quarter, Waterdrop reported net operating revenue of RMB 974.9 million, representing an increase of 38.4% year-over-year....
Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results
BEIJING, Dec. 3, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and nine months ended September 30, 2025. Financial and Operational Highlights for the Third Quarter of 2025 Substantial profit growth:...
